MHRA Patient Engagement, Philips Settlement and 1nhaler Funding

MHRA has published a consultation setting out how it will embed patient and public involvement across medicines and medical devices regulation. The move arrives alongside two stories that clarify where regulatory accountability now sits: Philips settling a US Department of Justice investigation for €288 million over its recalled CPAP and respiratory devices, and Scottish startup 1nhaler securing £2.2 million to progress its cardboard inhaler towards first regulatory approval. Taken together, these updates reveal where patient safety architecture, post-market enforcement and funding signals now converge.

MHRA Formalises Patient Involvement Architecture

MHRA's consultation outlines five operational areas where patient and public involvement will inform regulatory decisions: benefit-risk assessments, product information and labelling, regulatory science research priorities, regulatory guidance development, and communication strategies. The agency frames involvement not as consultation theatre but as input into technical decisions. It proposes standing expert patient committees, project-specific advisory groups, and ongoing engagement with patient organisations. Public comment runs until 10 February 2025.

The consultation arrives as MHRA continues to position itself as a globally aligned regulator open to iterative input. The patient involvement framework mirrors structural signals seen elsewhere, from FDA's patient preference studies to EMA's patient engagement frameworks. What matters here is scope: MHRA is signalling that patient and public input will inform not only clinical endpoints and labelling but also the architecture of regulatory science itself, including how post-market surveillance priorities are set.

For device manufacturers, this means technical documentation and post-market surveillance plans should anticipate patient-reported outcomes and usability findings as formal regulatory inputs, not optional supplementary evidence. If patient groups highlight usability concerns or real-world failure modes, those signals now feed directly into MHRA's benefit-risk assessments and post-market action priorities. The consultation explicitly invites views on whether MHRA should publish summaries of patient input, a transparency move that would make stakeholder concerns visible across the lifecycle.

Philips Settles CPAP Recall Investigation for €288 Million

Philips has settled with the US Department of Justice over its recall of millions of sleep apnoea and respiratory devices, paying €288 million to resolve allegations that it failed to notify FDA of quality problems and continued distributing devices it knew to be defective. The settlement includes allegations that Philips did not promptly file medical device reports as required under 21 CFR Part 803, and that it failed to implement corrective actions even after identifying foam degradation issues that posed respiratory and carcinogenic risks.

The financial penalty is secondary to the procedural precedent. The settlement makes explicit that failure to file timely MDRs, failure to act on post-market signals, and continued distribution after internal identification of defects constitute prosecutable conduct. For device manufacturers, the implications are clear: post-market surveillance systems must be operationally robust, not just documented. The gap between knowing there is a problem and filing the required reports is now a liability surface regulators will scrutinise in enforcement actions.

Philips' recall began in 2021 and affected approximately 5.5 million devices. The DOJ settlement includes a consent decree requiring Philips to overhaul its quality management system under FDA oversight, appoint an independent monitor, and submit to unannounced inspections. These conditions mirror the structural remediation FDA imposed in other high-visibility enforcement actions, signalling that regulators now expect systemic quality architecture changes, not just corrective actions on individual devices.

1nhaler Funding and the Cardboard Inhaler Pathway

Scotland-based 1nhaler has secured £2.2 million in follow-on funding to progress its pop-up cardboard inhaler towards first regulatory approval. The device combines a novel delivery mechanism with salbutamol, a well-established asthma medicine. The funding round will support late-stage development, manufacturing scale-up and regulatory submission preparation. 1nhaler positions the device as a lower-cost, environmentally sustainable alternative to traditional plastic inhalers, which aligns with growing sustainability pressures across European healthcare procurement.

The funding signal matters because it demonstrates investor confidence in a novel delivery device targeting a mature therapeutic area. For regulatory teams, the pathway here involves both device and drug approval, which means coordination across MHRA's medical devices and medicines divisions or parallel EU MDR and medicinal product submissions. The cardboard inhaler is not a minor modification of an existing predicate; it is a novel mechanism requiring human factors validation, shelf-life stability data for both the cardboard substrate and the drug formulation, and real-world usability evidence in paediatric and elderly populations.

1nhaler's progress also intersects with MHRA's recent consultation on adrenaline nasal sprays for school access, where usability and deployment risk were central concerns. Novel delivery devices that simplify administration or reduce cost face a dual regulatory burden: demonstrating equivalence or superiority in clinical endpoints while also proving that the new mechanism does not introduce usability failures in real-world settings. The cardboard inhaler must show that patients can reliably actuate the device, that dose delivery is consistent across environmental conditions, and that the device degrades predictably over its shelf life.

What This Means for Your Team

MHRA's patient involvement consultation, Philips' enforcement settlement, and 1nhaler's funding round clarify three operational realities. First, patient and public input is moving from optional consultation to formal regulatory architecture. MHRA's proposed standing committees and transparent publication of patient concerns mean that post-market signals from patient organisations will inform benefit-risk assessments and post-market surveillance priorities. Device manufacturers should integrate patient-reported outcomes and usability data into technical documentation early, not as supplementary evidence but as core inputs.

Second, the gap between identifying a defect internally and filing the required reports is now a liability surface regulators will prosecute. Philips' settlement makes explicit that continued distribution after internal identification of quality problems constitutes actionable conduct. For RA and QA teams, this means post-market surveillance systems must be operationally robust: signal detection, root cause analysis, corrective action initiation and regulatory reporting must run on defined timelines, with audit trails proving that decisions were made promptly.

Third, novel delivery devices face a dual burden of clinical equivalence and real-world usability. 1nhaler's cardboard inhaler must demonstrate not only that salbutamol delivery matches traditional inhalers but also that patients across age groups and dexterity levels can reliably actuate the device under real-world conditions. For device manufacturers working on novel mechanisms, this means human factors validation and post-market usability studies are not optional add-ons; they are core regulatory evidence that determines whether the device receives approval and whether it remains on the market.

Key Takeaways

• MHRA's patient involvement consultation formalises patient and public input across benefit-risk assessments, labelling, regulatory science priorities and post-market surveillance. RA teams should integrate patient-reported outcomes and usability data as core regulatory evidence, not optional supplements.
• Philips' €288 million DOJ settlement clarifies that failure to file timely MDRs and continued distribution after internal defect identification constitute prosecutable conduct. Post-market surveillance systems must operationalise signal detection, root cause analysis and regulatory reporting on documented timelines with full audit trails.
• 1nhaler's £2.2 million funding round demonstrates investor confidence in novel delivery mechanisms, but the regulatory pathway involves dual burdens: clinical equivalence and real-world usability validation across patient populations and environmental conditions.
• The convergence of patient involvement frameworks, enforcement precedents and novel device approvals reveals where post-market accountability architecture is heading: transparent stakeholder engagement, rapid corrective action timelines, and usability validation as core regulatory evidence.

These updates clarify where regulatory expectations, enforcement priorities and market signals now align. MHRA's consultation, Philips' settlement and 1nhaler's funding round reveal that post-market accountability is no longer a compliance afterthought. For device manufacturers, the operational challenge is integrating patient input, operationalising signal detection and validating real-world usability as core regulatory architecture, not reactive responses to enforcement actions or market failures. The teams that build these capabilities now will navigate the next decade of post-market scrutiny with structural advantage.